Howard University

BRIDGEWATER, N.J., Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity in clinical studies. The investment over 10 years is aimed at strengthening Centers of Excellence in clinical study diversity at Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine. Funding will be used to hire clinical research staff, establish infrastructure such as online chat services and pharmacy upgrades, create customized training programs, and more. Each of the Centers of Excellence have their own specific needs, which will help them harness their insights into the underrepresented communities they serve as they seek to increase representation and improve diversity in clinical studies. Lionel Bascles SVP, Global Head of Clinical Trials and Operations, Sanofi "At Sanofi, our mission is to chase the miracles of science to improve people's lives, and this means all people's lives, regardless of their race or ethnicity. By partnering with these three esteemed Historically Black College and University medical schools, we hope to facilitate new inroads to communities that have been underrepresented in healthcare for far too long. Increasing diversity and inclusion is essential to the research and development of medicines and vaccines for people of all backgrounds." Valerie Montgomery Rice, MD, FACOG President and CEO, Morehouse School of Medicine "Morehouse School of Medicine is exceptionally grateful to Sanofi for this investment in our clinical study diversity Center of Excellence. We look forward to a robust partnership as we work to increase diversity in clinical studies and develop advanced opportunities for researchers, leading to greater health equity. More diversity in clinical studies will ensure traditionally underserved populations receive the very latest cutting-edge therapeutic innovations." Sanofi is a global innovator in the Diversity, Equity and Inclusion space, including by pioneering the international effort A Million Conversations to examine trust gaps in the healthcare system. In the U.S., Sanofi and the National Association for the Advancement of Colored People (NAACP) announced a strategic partnership in July that is aimed at advancing health equity for Black and underserved communities. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY Media Relations Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Evan Berland | +1 215 432 0234 | [email protected] Timothy Gilbert | + 1 516 521 2929 | [email protected] Investor Relations Thomas Kudsk Larsen |+ 44 7545 513 693 | [email protected] Aliz é Kaisserian | + 33 6 47 04 12 11 | [email protected] Arnaud Delépine | + 33 6 73 69 36 93 | [email protected] Corentine Driancourt | + 33 6 40 56 92 21 | [email protected] Felix Lauscher | + 1 908 612 7239 | [email protected] Tarik Elgoutni| + 1 617 710 3587 | [email protected] Nathalie Pham | + 33 7 85 93 30 17 | [email protected] Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. SOURCE Sanofi WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEWNAN, Ga., Oct. 3, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Sabrina Rene, MD, FACE is acknowledged as a Pinnacle Professional Member for her contributions in Endocrinology. Continue Reading Sabrina Rene Dr. Sabrina Rene is a trailblazer in the field of endocrinology, dedicated to providing top-notch care to her local community. With a wealth of expertise in endocrine disorders and diabetes management, Dr. Rene has established herself as a trusted medical practitioner. She is a specialist in endocrinology, diabetes, PCOS, thyroid cancer, endocrine disrupting chemicals, thyroid ultrasound interpretations, and performing fine needle aspiration and biopsies of thyroid nodules. Armed with a Bachelor of Arts from New York University and a Doctor of Medicine from Howard University, Dr. Rene embarked on a journey of medical excellence. She further honed her skills through a rigorous residency at the prestigious Mayo Clinic, followed by a fellowship at Emory University, where she specialized in endocrinology. As a Fellow of the American College of Endocrinology (FACE) and a member of esteemed organizations such as the Endocrine Society; the National Medical Association (NMA); and the American Association of Clinical Endocrinologists, Dr. Rene remains at the forefront of advancements in her field. Board-certified in Endocrinology, diabetes, metabolism, and a certified expert in endocrine-disrupting chemicals, her dedication to continuing education ensures that she stays abreast of the latest developments and technologies in endocrinology. Touting more than 24 years of experience, Dr. Rene has been in private practice for five years, is co-owner of a group private practice for the last 10 years, and has been working in healthcare since 2018. Her extraordinary achievements have been punctuated with numerous awards and accolades including Top Doctors of America since 2018 and Best in Georgia magazine for endocrinology in April 2024. Beyond her professional commitments, Dr. Rene finds joy in traveling, especially to St. Lucia, and exploring new cultures, art, and music. She was also a member of the church choir. Her passion for holistic healthcare is reflected in her approach to patient care, where she considers not just the physical symptoms but also the overall well-being of her patients. The doctor said that her faith in God helps her to see the humanity and dignitiy in every patient. "This enables me to show compassion and empathy during difficult health crisis. I strive towards a thorough analysis of the endocrine condition coupled with education of the patient to understand their diagnosis," she explained. Dr. Rene's vision for the future includes conducting clinical research with a focus on endocrine-disrupting chemicals, aiming to shed light on their impact on human health. With a philosophy rooted in a holistic approach to medicine, she remains committed to providing comprehensive care to her patients, addressing both their medical needs and overall wellness. To her dear husband Andre, her parents, and brother, Dr. Rene expresses heartfelt gratitude for their unwavering love and support. She also thanks her many professional coaches, including Dr. Catherine Woodhouse, friends, and family for their encouragement throughout her journey which she notes has been instrumental in her pathway to success, and she looks forward to continuing to make a difference in the lives of her patients and community. Dr. Sabrina Rene's dedication to excellence and holistic healthcare sets her apart as a leader in the field of endocrinology, ensuring that her patients receive the highest quality of care and support. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TAMPA, Fla.--( BUSINESS WIRE )--Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM) ™ solutions, has noted a marked increase in the number of large health systems utilizing RPM. The innovative technology company understands the need for healthcare systems to justify the investment in a remote patient monitoring program. Sometimes these organizations can get overwhelmed when only considering costs, but there are many factors that provide a true picture of the ROI of RPM. There can be both short-and long-term ROI gained from RPM because RPM can help lower costs, produce revenue, and improve patient outcomes by providing instant data to help make real-time care decisions. Knowing how RPM affects finances can help healthcare providers make better decisions and improve their organization’s effectiveness. $27,000 or more Per Patient Cost Savings using RPM Brockton Hospital in Massachusetts began using a remote care program to track 25 to 30 Congestive Heart Failure (CHF) patients and was hoping to reduce its 30-day readmission rates to less than 25%. The reduction meant that no more than eight patients could be readmitted. The outcomes vastly exceeded the objective. Readmissions were reduced to zero, with no patients who were enrolled in the study were readmitted to the hospital. Zero readmissions represented a significant decrease in total medical expenses. The cost of a 30-day hospitalization is $27,000 per patient, so Brockton achieved a cost avoidance savings of $216,000.12. 1 $1,300 or more Per Patient Per Year in New Revenue using RPM Any practice, health system or healthcare organization with a National Provider Identifier (NPI) number can bill the Centers for Medicare and Medicaid Services (CMS) for reimbursement of services using certain CPT codes that are specifically for RPM. This can provide new revenue of more than $1,300 2 per patient per year when the claims are filed appropriately. Smart Meter has developed an RPM Calculator for healthcare professionals to see how much revenue they could be generating by billing CMS for RPM services utilizing these CPT codes. RPM Revenue Calculator - Smart Meter (smartmeterrpm.com) The use of RPM continues to grow rapidly and with that comes the increased knowledge to manage the programs in more efficient ways, leading to better ROI and more patients benefiting and improving because of the program. Earlier this year, Sage Growth Partners surveyed 141 healthcare executives and 90% said an RPM program has yielded a positive ROI. And respondents also said that proven implementation processes deliver predictable, low-risk methods for starting a program, with 90% of them using an external partner for RPM and CCM. In comparison, in a similar Sage Growth Partners survey from three years ago, only 60 percent of medical practice physicians and managers said RPM had a high return on investment. “ When considering an RPM program, healthcare organizations should investigate all the challenges and benefits,” said Smart Meter CEO Casey Pittock. “ Once they do that, we feel confident they will see how the benefits of RPM, both financially and clinically, can provide a positive ROI. Smart Meter currently supplies hundreds of RPM and CCM companies with the data, devices, and services to help them deliver a positive ROI for their healthcare customers who are embracing RPM.” A1c Reduced by 2.8% for Improved Patient Outcomes In addition to financial returns, RPM also provides clinical returns that lead to fewer hospital readmissions and reduction in overall healthcare costs. In a Howard University study of patients with diabetes using the iGlucose®, 70% of high-risk participants lowered their A1c by an average of 2.8% within 90 days 3 . A 30-day study by the University of Arkansas for Medical Sciences of 59 pregnant women with Type 1 or Type 2 diabetes, who frequently tested with Smart Meter’s cellular-enabled iGlucose® glucometer showed an increased satisfaction with their diabetes management. Eighty-six percent of participants noted that the automatic transmission of blood glucose results to their physician helped them better maintain their condition. Participants who used the iGlucose glucose meter demonstrated increased positive appraisal of diabetes and general life satisfaction Baum Consulting Services implemented an RPM program using Smart Meter’s cellular devices and saw excellent results. One of the highlights of the program included a male patient in his 70s with hypertension, who, after two out-of-range blood pressure readings had adjustments made to his medication was able to avoid an emergency room visit. Another patient with diabetes had an A1c of 10.4 before starting the program but was able to reduce that to 6.6 in about a year and a half. As the healthcare industry continues to evolve, embracing innovative technologies like RPM will be crucial for improving patient care and operational efficiency. By investing in RPM, healthcare organizations and practitioners can stay ahead of the curve, delivering high-quality care in an increasingly digital world. About Smart Meter, LLC Smart Meter is the trusted supplier of cellular Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solutions. We empower a nationwide network of Smart Partners ™ who are working directly with healthcare providers to transform patient care. Millions of vital health data readings are reliably delivered across our platform every day to enable real-time, better-informed health care. Our proprietary patient-friendly, cellular FDA-registered monitoring devices are connected to an exclusive AT&T 4/5G private data network to ensure an engaging patient experience for improved adherence. For more information, visit www.SmartMeterRPM.com 1 - https://www.ehidc.org/sites/default/files/resources/files/ROIPGHD_7.26.18_final.pdf 2 - Based on the average of current reimbursement rates for CPT 99453 ( $18.77), CPT99454 ( $62.44), and CPT 99457 ( $51.61). 3 - The Benefits of Remote Monitoring of Real Time Blood Glucose Data Using iGlucose System in Managing Patients with Diabetes, Howard University Diabetes Center.